Zolmitriptan
Selective Serotonin (5ht1) Agonists
Sold as ZOMIG · ZOMIG RAPIMELT
- Drug class
- Selective Serotonin (5ht1) Agonists
- Availability
- Prescription only
- Routes
- Oral, Nasal
- Markets covered
- 3
- Products on record
- 70
- FDA reports (12 mo)
- 323
Overview
Zolmitriptan is an active pharmaceutical ingredient in the Selective Serotonin (5ht1) Agonists group (N02CC). The information below is compiled per regulator from the product labels on record, with direct links to the original documents.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 45 | May 22, 2026 |
| CA Canada | Health Canada | 22 | March 19, 2026 |
| US United States | FDA | 3 | May 2, 2025 |
GBUnited Kingdom· MHRA
45 products
Uses
1 THERAPEUTIC INDICATION Zolmitriptan Grünenthal Nasal Spray is indicated for the acute treatment of migraine with or without aura in adults and adolescents aged 12 years and older. 4.
How to take
CACanada· Health Canada
22 products
Uses
3 Pediatrics 04/2024 TABLE OF CONTENTS Sections or subsections that are not applicable at the time of authorization are not listed. RECENT MAJOR LABEL CHANGES ............................................................................................
2 TABLE OF CONTENTS .............................................................................................................. 2 PART I: HEALTH PROFESSIONAL INFORMATION ......................................................................
5 1 INDICATIONS ............................................................................................................... 5 2 CONTRAINDICATIONS .................................................................................................
5 3 SERIOUS WARNINGS AND PRECAUTIONS BOX ............................................................ 6 4 DOSAGE AND ADMINISTRATION ................................................................................. 8 5 OVERDOSAGE..............................................................................................................
USUnited States· FDA
3 products
Uses
1 INDICATIONS AND USAGE ZOLMITRIPTAN NASAL SPRAY is indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years of age and older. Limitations of Use Only use ZOLMITRIPTAN NASAL SPRAY if a clear diagnosis of migraine has been established.
If a patient has no response to ZOLMITRIPTAN NASAL SPRAY treatment for the first migraine attack, reconsider the diagnosis of migraine before ZOLMITRIPTAN NASAL SPRAY is administered to treat any subsequent attacks. ZOLMITRIPTAN NASAL SPRAY is not indicated for the prevention of migraine attacks.
Safety and effectiveness of ZOLMITRIPTAN NASAL SPRAY have not been established for cluster headache. 2) ] . ZOLMITRIPTAN NASAL SPRAY is a serotonin (5-HT) 1B/1D receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults and pediatric patients 12 years and older (1) Limitations of Use: Use only after a clear diagnosis of migraine has been established (1) Not intended for the prophylactic therapy of migraine (1) Not indicated for the treatment of cluster headache (1) Not recommended in patients with moderate to severe hepatic impairment (1)
Drug interactions
Known interactions involving Zolmitriptan. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL217270085 · revised March 6, 2026
- [2]Health Canada (DPD) · 02238660 · revised July 22, 2025
- [3]FDA DailyMed · 05a40502-149d-41… · revised April 30, 2019 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.